Supply Chain | September 28, 2021
SpeeDx and SynGenis partner for custom oligonucleotide synthesis
The investment will increase SpeeDx internal capacity to scale up manufacturing
The investment will increase SpeeDx internal capacity to scale up manufacturing
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
A high-value proposition recyclable film packed with industry-leading barrier and metal bond performance, sustainability quotient and U.S. FDA compliant
The Mission will simplify hospital processes and will increase Ease of Living. Under this, every citizen will get a digital health ID and their health record will be digitally protected.
This project will be conducted at the “NURA,” a health screening centre that Fujifilm opened in India in February this year
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
The company does not expect the outcome of this inspection to impact its plans
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
It paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
Subscribe To Our Newsletter & Stay Updated
